NEWS

NEWS 2020.10.1 Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.

Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter OtsukaPharmaceutical) on October 1st 2020. Under this agreement, Rebirthel will provide its patented technology to Otsuka Pharmaceutical, and Otsuka Pharmaceutical will utilize this technology for the development of the cancer immunotherapy using allogeneic T cells. For details, please refer to the attached press release.

See the list of NEWS